Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported its results for the second quarter and six months ended June 30, 2007. Product revenues were $10.4 million for the second quarter of 2007, representing a 4% decrease over product revenues of $10.8 million for the second quarter of 2006. For the first six ...
Integra LifeSciences Holdings Corporation and IsoTis, Inc.
Plainsboro, New Jersey and Irvine, California (ots/PRNewswire) - - Creating a Global Leader in Orthobiologics Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") and IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis") announced today a definitive agreement whereby Integra would acquire IsoTis in an all cash transaction. This strategic combination, unanimously approved by the Board of Directors of IsoTis, ...
Carlyle Capital Corporation Limited
Guernsey (ots/PRNewswire) - Carlyle Capital Corporation Limited (Amsterdam: CCC; GG00B1VYV826) (the"Company") today confirmed that it will hold a conference call with financial analysts to present its second quarter 2007 financial results and to respond to questions on Wednesday, August 22, 2007 at 9:00 A.M. (EDT) (2:00 P.M. London). The call may be accessed by dialing (800)-310-6649 (North America) or +1-719-457-2693 ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDQ: ISOT), a leading orthobiologics company, will release its 2007 second quarter results before opening of trading on Tuesday, August 7, 2007. To discuss these results, the Company will conduct a conference call at 4:00 p.m. (Eastern Time) / 1:00 p.m. (Pacific Time)/ 10:00 p.m. (Central European Time). Dial in details will be provided in the Q2 2007 release on ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika today announced that the Company has received permission from the Food and Drug Administration of the United States (FDA) for the long term use of ISA247 in patients currently participating in the Company's Phase 2b kidney transplant (PROMISE) trial. The Company previously announced in June that it had also ...
King Of Prussia, Pennsylvania (ots/PRNewswire) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services (DRS) business in Europe. MDS Pharma Services will now offer full-service DRS consulting services to support development of new drugs and ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today that the European Agency for the Evaluation of Medicinal Products (EMEA) committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for ISA247 for the treatment of chronic, ...
Oss, The Netherlands (ots/PRNewswire) - Organon, the human healthcare business unit of Akzo Nobel (Euronext Amsterdam: AKZ), today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved rocuronium bromide, its neuromuscular blocking agent (NMBA) for use during general anesthesia, under the brand name Eslax(R). This drug has a fast onset of action and is one of the most widely used muscle ...
Minneapolis (ots/PRNewswire) - AGA Medical Corporation ("AGA") today announced that it has won its patent infringement lawsuit against Occlutech GmbH, headquartered in Jena, Germany, and DRABO Medizintechnik, located in Cologne, Germany. AGA is the owner of a European patent (EP 0 808 138) registered in Germany (DE 695 34 505) for intravascular occlusion devices ...
Takeda Pharmaceutical Company Limited
London (ots/PRNewswire) - Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease. "The breadth ...
Basel, Switzerland (ots/PRNewswire) - - First Anti-Anaemia Product Offering Simple Once-Monthly Maintenance Treatment Roche announced today that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD). The approval of MIRCERA results in a single marketing authorisation with unified ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company ("IsoTis"), today announced that it has concluded the squeeze-out merger of ISOTIS SA following an Extraordinary General Meeting of shareholders on July 23, 2007. As a result, ISOTIS SA has merged with and into IsoTis International SA, a wholly-owned subsidiary of IsoTis, and no longer exists as a separate legal entity. After ...
Boehringer Ingelheim and Pfizer
Ingelheim, Germany (ots/PRNewswire) - - Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market SPIRIVA(R) Respimat(R) in the European Union for people with chronic obstructive pulmonary disease (COPD). This positive ...
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today that the Company has completed recruitment of its pivotal Phase 3 European/Canadian psoriasis trial (ESSENCE). As of July 20, 2007, the Company closed recruitment at 638 patients. The patient population is made up of 228 Canadian patients, 294 patients from Germany and 116 patients from ...
Sydney, Australia (ots/PRNewswire) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal ...
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival of Previously Untreated Patients Beyond One Year Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the first-line use of Avastin in the ...
Oss, The Netherlands (ots/PRNewswire) - Organon, the human healthcare business unit of Akzo Nobel, announced today that the Marketing Authorization Application (MAA) for sugammadex has been accepted for review by the European Medicines Agency (EMEA). This novel selective relaxant binding agent (SRBA) is specifically designed to reverse the effects of the muscle ...
Evry, France (ots/PRNewswire) - In preparation for the application for the listing of its shares on Eurolist by Euronext, Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that its document de base was registered on July 18, 2007 by the Autorité des marchés financiers (AMF) under number ...
Bethesda, Maryland (ots/PRNewswire) - - Company Expects Four Antibodies in Clinical Development by End of 2007 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today the promotion of Carsten Reinhardt, M.D. from Senior Vice President of Clinical ...
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV announced today that the European Medicines Agency (EMEA) has accepted for review a Marketing Authorization Application (MAA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia (NP), including ...
World Glaucoma Association (WGA)
Singapore (ots/PRNewswire) - Today, leading experts from the World Glaucoma Association (WGA) launched the group's first consensus on intraocular pressure (IOP). The panel recognized that elevated IOP is the leading risk factor for glaucoma progression and accurate measurement of IOP plays a key role in assessing glaucoma risk and disease management. The panel's ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company is the First Company in the World to Produce Recombinant Apo AI, a Next Generation Cardiovascular Therapy, Using Plants SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company, today announced it has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AI(Milano) (collectively referred to as Apo AI) ...
PDUFA date of 4th March 4, 2008 established Lugano (ots) - Helsinn's Top Management today announced that the supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting was accepted for filing by the United States Food and Drug Administration (FDA). Aloxi is approved by the FDA ...
Amsterdam (ots/PRNewswire) - - Deputy Mayor of Amsterdam Starts Next Phase of Avantium's Biofuels Research Program. During the visit of the Deputy Mayor of Amsterdam, Mr. Lodewijk Asscher, Avantium has announced that it is active in developing a novel generation of biofuels. The Deputy Mayor of Amsterdam, Lodewijk Asscher, said: "The city of Amsterdam is delighted with the progress of Avantium. Avantium ...
University of Massachusetts Medical School
Worcester, Massachusetts (ots/PRNewswire) - - ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate prophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among ...
Paris, France (ots/PRNewswire) - - EXCLAIM is the First International Study to Show That Extended Thromboprophylaxis Reduces VTE Risk in Acutely-ill Medical Patients With a Statistically Significant 44% Sanofi-aventis announced today the results of the EXCLAIM (EXtended CLinical prophylaxis in Acutely ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...